Form 4 KALOBIOS PHARMACEUTICALS For: Nov 20 Filed by: Shkreli Martin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
KaloBios Pharma (KBIO) Could Drop 50% By Early Next Week: Tim Sykes
November 24, 2015 12:46 PM ESTTim Sykes thinks KaloBios Pharma (NASDAQ: KBIO) could drop 50% by early next week, according to the New York... More
KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice
November 23, 2015 5:46 PM ESTThe NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).
Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More
KaloBios Pharma (KBIO) CEO Shkreli Purchased 5,000 Shares
November 23, 2015 3:12 PM ESTKaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli disclosed a recent stock purchase.
In a Form 4 filing made today, Shkreli purchased 5,000 shares of the company's stock on November 20th for $18.88 per share.
The filing is embedded below:
... More